{
    "Case ID": "086870",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent validity dispute"
    ],
    "Legal_Issue": [
        "Obviousness of the '647 patent"
    ],
    "Governing_Law": [
        "Section 28.3 of the Patent Act"
    ],
    "Procedural_Stage": [
        "Application stage"
    ],
    "Evidence_Assessment": [
        "Expert testimony, prior art analysis"
    ],
    "Decision_Outcome": [
        "'647 patent is not invalid due to obviousness"
    ],
    "Burden_of_Proof": [
        "On the party alleging invalidity (Ranbaxy)"
    ],
    "Credibility_Factor": [
        "Expert testimony credibility considered"
    ],
    "Legal_Rule": [
        "A patent claim must not be obvious to a person skilled in the art"
    ],
    "Standard_of_Review": [
        "Obvious to try test"
    ],
    "Procedural_Issue": [
        "Filing of application by AstraZeneca to dispute invalidity allegation"
    ],
    "Grounds_for_Claim": [
        "Allegation that the patent was obvious at the time of filing"
    ],
    "Outcome_on_Merits": [
        "Patent upheld as valid"
    ],
    "Decision_Maker": [
        "Court"
    ],
    "Judicial_Review_Outcome": [
        "Application granted in favor of AstraZeneca"
    ],
    "Review_Standard": [
        "Obvious to try"
    ],
    "Procedural_Fairness_Assessment": [
        "Fair evaluation of expert testimonies and legal arguments"
    ],
    "Key_Evidence_Considered": [
        "Prior art, complexity of formulation development, expert opinions"
    ],
    "Legal_Framework": [
        "Canadian Patent Act"
    ],
    "Applicant_Challenge": [
        "AstraZeneca challenged Ranbaxy's allegation of obviousness"
    ],
    "Court_Result": [
        "AstraZeneca's application granted"
    ],
    "Legal_Rule_Source": [
        "Statutory: Section 28.3, Patent Act"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Ranbaxy claimed the invention was obvious based on prior art"
    ],
    "Evidence_Type": [
        "Documentary evidence, expert testimony"
    ],
    "Remedy_Requested": [
        "Prevention of generic approval until patent expiry"
    ],
    "Outcome": [
        "Ranbaxy prohibited from obtaining regulatory approval until patent expires"
    ],
    "Decision_Authority": [
        "Superior Court or Federal Court (implied)"
    ],
    "Remedy_Sought": [
        "Injunction against approval of generic drug"
    ],
    "Resolution_Mechanism": [
        "Judicial determination on patent validity"
    ],
    "Legal_Provision": [
        "Section 28.3"
    ],
    "Authority": [
        "Patent Act"
    ],
    "Claimant_Status": [
        "Patent holder (AstraZeneca)"
    ],
    "Legal_Provision_Cited": [
        "Section 28.3 of the Patent Act"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Obviousness of patent claims"
    ],
    "Applicable_Process": [
        "Notice of allegations under patent linkage regulations"
    ],
    "Outcome_of_Review": [
        "Patent found valid, no invalidity established"
    ],
    "Pending_Relief_or_Application": [
        "Application to prohibit generic entry"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Obviousness standard under Canadian patent law"
    ]
}